<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35724689</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-4286</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme</Title><ISOAbbreviation>Horm Metab Res</ISOAbbreviation></Journal><ArticleTitle>Diabetes and COVID-19: Short- and Long-Term Consequences.</ArticleTitle><Pagination><StartPage>503</StartPage><EndPage>509</EndPage><MedlinePgn>503-509</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/a-1878-9566</ELocationID><Abstract><AbstractText>When the corona pandemic commenced more than two years ago, it was quickly recognized that people with metabolic diseases show an augmented risk of severe COVID-19 and an increased mortality compared to people without these comorbidities. Furthermore, an infection with SARS-CoV-2 has been shown to lead to an aggravation of metabolic diseases and in single cases to new-onset metabolic disorders. In addition to the increased risk for people with diabetes in the acute phase of COVID-19, this patient group also seems to be more often affected by long-COVID and to experience more long-term consequences than people without diabetes. The mechanisms behind these discrepancies between people with and without diabetes in relation to COVID-19 are not completely understood yet and will require further research and follow-up studies during the following years. In the current review, we discuss why patients with diabetes have this higher risk of developing severe COVID-19 symptoms not only in the acute phase of the disease but also in relation to long-COVID, vaccine breakthrough infections and re-infections. Furthermore, we discuss the effects of lockdown on glycemic control.</AbstractText><CopyrightInformation>The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steenblock</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9635-4860</Identifier><AffiliationInfo><Affiliation>Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassanein</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Diabetes and Endocrinology, Dubai Hospital, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Emran G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Endocrinology and Diabetology, King's College Hospital London, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaman</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Building 6, Nesmah Technology, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamel</LastName><ForeName>Margrit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbir</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Harefield Hospital, Harefield, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorke</LastName><ForeName>Dietrich E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cellular Biology, Khalifa University, Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rock</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>College of Medicine &amp; Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Everett</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology and Infectious Diseases, Khalifa University, Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bejtullah</LastName><ForeName>Saqipi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Unit, College Heimerer, Prishtina, Republic of Kosovo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heimerer</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Unit, College Heimerer, Prishtina, Republic of Kosovo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahirukaj</LastName><ForeName>Ermal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beqiri</LastName><ForeName>Petrit</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Unit, College Heimerer, Prishtina, Republic of Kosovo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bornstein</LastName><ForeName>Stefan R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences &amp; Medicine, King's College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Deutsche Forschungsgemeinschaft</GrantID><Agency>288034826,314061271</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Horm Metab Res</MedlineTA><NlmUniqueID>0177722</NlmUniqueID><ISSNLinking>0018-5043</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>20</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35724689</ArticleId><ArticleId IdType="pmc">PMC9363150</ArticleId><ArticleId IdType="doi">10.1055/a-1878-9566</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Steenblock C, Schwarz PE H, Ludwig B et al.COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021;9:786&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489878</ArticleId><ArticleId IdType="pubmed">34619105</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechmann N, Barthel A, Schedl A et al.Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes Endocrinol. 2022;10:221&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8803381</ArticleId><ArticleId IdType="pubmed">35114136</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucher J, Kleinridders A, Kahn C R. Insulin receptor signaling in normal and Insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6:a009191. doi: 10.1101/cshperspect.a009191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a009191</ArticleId><ArticleId IdType="pmc">PMC3941218</ArticleId><ArticleId IdType="pubmed">24384568</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser N, Legrand-Poels S, Piette J et al.Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">24798950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein S R, Rubino F, Ludwig B et al.Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nat Metab. 2021;3:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">33633407</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos A, Magro D O, Evangelista-Poderoso R et al.Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021;13:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919999</ArticleId><ArticleId IdType="pubmed">33648564</ArticleId></ArticleIdList></Reference><Reference><Citation>Montefusco L, Ben Nasr M, D&#x2019;Addio F et al.Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3:774&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931026</ArticleId><ArticleId IdType="pubmed">34035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Langouche L, Van den Berghe G, Gunst J. Hyperglycemia and insulin resistance in COVID-19 versus non-COVID critical illness: are they really different? Crit Care. 2021;25:437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8680062</ArticleId><ArticleId IdType="pubmed">34920750</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurenzi A, Caretto A, Molinari C et al.No evidence of long-term disruption of glycometabolic control after SARS-CoV-2 infection. J Clin Endocrinol Metab. 2021;107:e1009&#x2013;e1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691144</ArticleId><ArticleId IdType="pubmed">34718627</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller J A, Gross R, Conzelmann C et al.SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3:149&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">33536639</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadir MM F, Bhondeley M, Beatty W et al.SARS-CoV-2 infection of the pancreas promotes thrombofibrosis and is associated with new-onset diabetes. JCI Insight. 2021;6:e151551. doi: 10.1172/jci.insight.151551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151551</ArticleId><ArticleId IdType="pmc">PMC8410013</ArticleId><ArticleId IdType="pubmed">34241597</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenblock C, Richter S, Berger I et al.Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun. 2021;12:3534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8192507</ArticleId><ArticleId IdType="pubmed">34112801</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinserling V A, Bornstein S R, Narkevich T A et al.Stillborn child with diffuse SARS-CoV-2 viral infection of multiple organs. IDCases. 2021;26:e01328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8570448</ArticleId><ArticleId IdType="pubmed">34777995</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett C E, Koyama A K, Alvarez P et al.Risk for newly diagnosed diabetes&gt;30 days after SARS-CoV-2 infection among persons aged&lt;18 years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757617</ArticleId><ArticleId IdType="pubmed">35025851</ArticleId></ArticleIdList></Reference><Reference><Citation>Birabaharan M, Kaelber D C, Pettus J H et al.Risk of new-onset type 2 diabetes in 600&#x2009;055 people after COVID-19: a cohort study. Diabetes Obes Metabol. 2022;24:1176&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035030</ArticleId><ArticleId IdType="pubmed">35112782</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez A, Jansen-Chaparro S, Saigi I et al.Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6:9&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24103089</ArticleId></ArticleIdList></Reference><Reference><Citation>Catriona C, Paolo P. SARS-CoV-2 induced post-translational protein modifications: a trigger for developing autoimmune diabetes? Diabetes Metab Res Rev. 2022;38:e3508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015335</ArticleId><ArticleId IdType="pubmed">34990520</ArticleId></ArticleIdList></Reference><Reference><Citation>Darrah E, Andrade F. Rheumatoid arthritis and citrullination. Curr Opin Rheumatol. 2018;30:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5848217</ArticleId><ArticleId IdType="pubmed">28937414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollid L M, Jabri B. Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders. Curr Opin Immunol. 2011;23:732&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428143</ArticleId><ArticleId IdType="pubmed">21917438</ArticleId></ArticleIdList></Reference><Reference><Citation>James E A, Pietropaolo M, Mamula M J. Immune recognition of beta-cells: neoepitopes as key players in the loss of tolerance. Diabetes. 2018;67:1035&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961411</ArticleId><ArticleId IdType="pubmed">29784651</ArticleId></ArticleIdList></Reference><Reference><Citation>Strollo R, Vinci C, Arshad M H et al.Antibodies to post-translationally modified insulin in type 1 diabetes. Diabetologia. 2015;58:2851&#x2013;2860.</Citation><ArticleIdList><ArticleId IdType="pubmed">26350612</ArticleId></ArticleIdList></Reference><Reference><Citation>Strollo R, Vinci C, Napoli N et al.Antibodies to oxidized insulin improve prediction of type 1 diabetes in children with positive standard islet autoantibodies. Diabetes Metab Res Rev. 2019;35:e3132.</Citation><ArticleIdList><ArticleId IdType="pubmed">30693639</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A V, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr. 2021;15:869&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn K G, Brokstad K A et al.Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavli A, Theodoridou M, Maltezou H C. Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52:575&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8093949</ArticleId><ArticleId IdType="pubmed">33962805</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L, Tosto-Mancuso J, Wood J et al.Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil. 2022;101:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi M S, Omrani O A, Fawzy N A et al.Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28:657&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal R, Gubbi S, Koch C A. COVID-19 and chronic fatigue syndrome: An endocrine perspective. J Clin Transl Endocrinol. 2022;27:100284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8641402</ArticleId><ArticleId IdType="pubmed">34877261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Bitna H, Kim S W et al.Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea. BMC Infect Dis. 2022;22:93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8793328</ArticleId><ArticleId IdType="pubmed">35086489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman S N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4:e2111417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J P, Chesney E, Oliver D et al.Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C H, Murray B, Varsavsky T et al.Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Korompoki E, Gavriatopoulou M, Hicklen R S et al.Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect. 2021;83:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118709</ArticleId><ArticleId IdType="pubmed">33992686</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriatopoulou M, Korompoki E, Fotiou D et al.Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;20:493&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383117</ArticleId><ArticleId IdType="pubmed">32720223</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan R K, Kashour T, Hamid Q et al.Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol. 2021;12:686029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Du Z, Zhu F et al.Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395:e52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270177</ArticleId><ArticleId IdType="pubmed">32171074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal J, Ghosh A, Bhatt S P et al.High prevalence of post COVID-19 fatigue in patients with type 2 diabetes: a case-control study. Diabetes Metab Syndr. 2021;15:102302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8462068</ArticleId><ArticleId IdType="pubmed">34626924</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A V, Misra A. Post COVID-19 syndrome (&#x201c;Long COVID&#x201d;) and diabetes: challenges in diagnosis and management. Diabetes Metab Syndr. 2021;15:102235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8317446</ArticleId><ArticleId IdType="pubmed">34384972</ArticleId></ArticleIdList></Reference><Reference><Citation>Oz M, Lorke D E. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Biomed Pharmacother. 2021;136:111193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836742</ArticleId><ArticleId IdType="pubmed">33461019</ArticleId></ArticleIdList></Reference><Reference><Citation>Swamy S, Koch C A, Hannah-Shmouni F et al.Hypertension and COVID-19: updates from the era of vaccines and variants. J Clin Transl Endocrinol. 2022;27:100285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8645507</ArticleId><ArticleId IdType="pubmed">34900602</ArticleId></ArticleIdList></Reference><Reference><Citation>Oz M, Lorke D E, Kabbani N. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. Pharmacol Ther. 2021;221:107750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854082</ArticleId><ArticleId IdType="pubmed">33275999</ArticleId></ArticleIdList></Reference><Reference><Citation>Carboni E, Carta A R, Carboni E. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Med Hypotheses. 2020;140:109776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175844</ArticleId><ArticleId IdType="pubmed">32344313</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangarajan S, Bone N B, Zmijewska A A et al.Metformin reverses established lung fibrosis in a bleomycin model. Nat Med. 2018;24:1121&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6081262</ArticleId><ArticleId IdType="pubmed">29967351</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsaknis G, Siempos I I, Kopterides P et al.Metformin attenuates ventilator-induced lung injury. Crit Care. 2012;16:R134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580719</ArticleId><ArticleId IdType="pubmed">22827994</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Walther F J, Sengers R M et al.Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response. Am J Physiol Lung Cell Mol Physiol. 2015;309:L262&#x2013;L270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525117</ArticleId><ArticleId IdType="pubmed">26047641</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh T K, Song I A. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study. Acta Diabetol. 2021;58:771&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7882044</ArticleId><ArticleId IdType="pubmed">33582839</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouse A B, Grimes T, Li P et al.Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front Endocrinol (Lausanne) 2020;11:600439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7838490</ArticleId><ArticleId IdType="pubmed">33519709</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh A, Randall M D. Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:2642&#x2013;2656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111510</ArticleId><ArticleId IdType="pubmed">35122284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariyanto T I, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med. 2020;19:100290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434427</ArticleId><ArticleId IdType="pubmed">32844132</ArticleId></ArticleIdList></Reference><Reference><Citation>Smati S, Tramunt B, Wargny M et al.COVID-19 and diabetes outcomes: rationale for and updates from the CORONADO study. Curr Diab Rep. 2022;22:53&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853410</ArticleId><ArticleId IdType="pubmed">35171448</ArticleId></ArticleIdList></Reference><Reference><Citation>Solerte S B, Di Sabatino A, Galli M et al.Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020;57:779&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275134</ArticleId><ArticleId IdType="pubmed">32506195</ArticleId></ArticleIdList></Reference><Reference><Citation>Oktay A A, Akturk H K, Paul T K . South Dartmouth (MA): 2000. Diabetes, cardiomyopathy, and heart failure. In: Feingold KR, Anawalt B, Boyce A et al. (eds). Endotext.</Citation></Reference><Reference><Citation>Alshnbari A, Idris I. Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? - targeting hyperinflammation. Curr Med Res Opin. 2022;38:357&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8787835</ArticleId><ArticleId IdType="pubmed">35057687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasrija R, Naime M. Resolving the equation between mucormycosis and COVID-19 disease. Mol Biol Rep. 2022;49:3349&#x2013;3356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782700</ArticleId><ArticleId IdType="pubmed">35064406</ArticleId></ArticleIdList></Reference><Reference><Citation>Chander J, Kaur M, Singla N et al.Mucormycosis: battle with the deadly enemy over a five-year period in India. J Fungi (Basel) 2018;4:46. doi: 10.3390/jof4020046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof4020046</ArticleId><ArticleId IdType="pmc">PMC6023269</ArticleId><ArticleId IdType="pubmed">29642408</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg D, Muthu V, Sehgal I S et al.Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021;186:289&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7862973</ArticleId><ArticleId IdType="pubmed">33544266</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R, Singh B, Bhadada S K et al.COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses. 2021;64:1452&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8447126</ArticleId><ArticleId IdType="pubmed">34133798</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen M, Lahane S, Lahane T P et al.Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021;69:244&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7933891</ArticleId><ArticleId IdType="pubmed">33463566</ArticleId></ArticleIdList></Reference><Reference><Citation>Divakar P K. Fungal taxa responsible for mucormycosis/&#x201d;black fungus&#x201d; among COVID-19 patients in India. J Fungi (Basel) 2021;7:641. doi: 10.3390/jof7080641.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof7080641</ArticleId><ArticleId IdType="pmc">PMC8402169</ArticleId><ArticleId IdType="pubmed">34436180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravani S A, Agrawal G A, Leuva P A et al.Rise of the phoenix: mucormycosis in COVID-19 times. Indian J Ophthalmol. 2021;69:1563&#x2013;1568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302276</ArticleId><ArticleId IdType="pubmed">34011742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M, Sarma D K, Shubham S et al.Mucormycosis in COVID-19 pandemic: risk factors and linkages. Curr Res Microb Sci. 2021;2:100057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8349419</ArticleId><ArticleId IdType="pubmed">34396355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Sharma A, Chakrabarti A. The emergence of post-COVID-19 mucormycosis in India: can we prevent it? Indian J Ophthalmol. 2021;69:1645&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8374792</ArticleId><ArticleId IdType="pubmed">34146000</ArticleId></ArticleIdList></Reference><Reference><Citation>John T M, Jacob C N, Kontoyiannis D P. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel) 2021;7:298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8071133</ArticleId><ArticleId IdType="pubmed">33920755</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianchandani R, Esfandiari N H, Ang L et al.Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69:2048&#x2013;2053.</Citation><ArticleIdList><ArticleId IdType="pubmed">32778570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamez-Perez H E, Quintanilla-Flores D L, Rodriguez-Gutierrez R et al.Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6:1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4515447</ArticleId><ArticleId IdType="pubmed">26240704</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakir M, Maan MH A, Waheed S. Mucormycosis in a patient with COVID-19 with uncontrolled diabetes. BMJ Case Rep. 2021;14:e245343. doi: 10.1136/bcr-2021-245343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-245343</ArticleId><ArticleId IdType="pmc">PMC8323390</ArticleId><ArticleId IdType="pubmed">34326123</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellingiri B, Jayaramayya K, Iyer M et al.COVID-19: A promising cure for the global panic. Sci Total Environ. 2020;725:138277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128376</ArticleId><ArticleId IdType="pubmed">32278175</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldin C, Ibrahim A S. Molecular mechanisms of mucormycosis - the bitter and the sweet. PLoS Pathog. 2017;13:e1006408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5542377</ArticleId><ArticleId IdType="pubmed">28771587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim A S, Spellberg B, Walsh T J et al.Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54:S16&#x2013;S22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286196</ArticleId><ArticleId IdType="pubmed">22247441</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N, Barda N, Kepten E et al.BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Eng. J Med. 2021;384:1412&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefan N. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Nat Rev Endocrinol. 2022;18:75&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8647056</ArticleId><ArticleId IdType="pubmed">34873287</ArticleId></ArticleIdList></Reference><Reference><Citation>Juthani P V, Gupta A, Borges K A et al.Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021;21:1485&#x2013;1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423430</ArticleId><ArticleId IdType="pubmed">34506735</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal U, Katikireddi S V, McCowan C et al.COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med. 2021;9:1439&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8480963</ArticleId><ArticleId IdType="pubmed">34599903</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefan N, Birkenfeld A L, Schulze M B. Global pandemics interconnected &#x2014; obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17:135&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">33479538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman S, Rahman M M, Miah M et al.COVID-19 reinfections among naturally infected and vaccinated individuals. Sci Rep. 2022;12:1438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8792012</ArticleId><ArticleId IdType="pubmed">35082344</ArticleId></ArticleIdList></Reference><Reference><Citation>Cena H, Fiechtner L, Vincenti A et al.COVID-19 pandemic as risk factors for excessive weight gain in pediatrics: the role of changes in nutrition behavior. a narrative review. Nutrients. 2021;13:4255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8707175</ArticleId><ArticleId IdType="pubmed">34959805</ArticleId></ArticleIdList></Reference><Reference><Citation>Dun Y, Ripley-Gonzalez J W, Zhou N et al.Weight gain in Chinese youth during a 4-month COVID-19 lockdown: a retrospective observational study. BMJ Open. 2021;11:e052451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8300557</ArticleId><ArticleId IdType="pubmed">34301671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H M, Jeong D C, Suh B K et al.The impact of the Coronavirus disease-2019 pandemic on childhood obesity and vitamin D status. J Korean Med Sci. 2021;36:e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7813584</ArticleId><ArticleId IdType="pubmed">33463095</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverii G A, Delli Poggi C, Dicembrini I et al.Glucose control in diabetes during home confinement for the first pandemic wave of COVID-19: a meta-analysis of observational studies. Acta Diabetol. 2021;58:1603&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219181</ArticleId><ArticleId IdType="pubmed">34159476</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofolo M, Aragona M, Rodia C et al.Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: a meta-analysis of observational studies. Diabetes Res Clin Pract. 2021;180:109066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8458100</ArticleId><ArticleId IdType="pubmed">34563586</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhu Navis J, Leelarathna L, Mubita W et al.Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England. Acta Diabetol. 2021;58:231&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567414</ArticleId><ArticleId IdType="pubmed">33067723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakonen E, Varimo T, Tuomaala A K et al.The effect of COVID-19 lockdown on the glycemic control of children with type 1 diabetes. BMC Pediatr. 2022;22:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8766349</ArticleId><ArticleId IdType="pubmed">35045807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Luo S, Zheng X et al.Glycemic control in children and teenagers with type 1 diabetes around lockdown for COVID-19: a continuous glucose monitoring-based observational study. J Diabetes Investig. 2021;12:1708&#x2013;1717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014845</ArticleId><ArticleId IdType="pubmed">33539665</ArticleId></ArticleIdList></Reference><Reference><Citation>Predieri B, Leo F, Candia F et al.Glycemic control improvement in Italian children and adolescents with type 1 diabetes followed through telemedicine during lockdown due to the COVID-19 pandemic. Front Endocrinol (Lausanne) 2020;11:595735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7793913</ArticleId><ArticleId IdType="pubmed">33424771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H P, Wong JS L, Selveindran N M et al.Impact of COVID-19 lockdown on glycaemic control and lifestyle changes in children and adolescents with type 1 and type 2 diabetes mellitus. Endocrine. 2021;73:499&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270233</ArticleId><ArticleId IdType="pubmed">34244903</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenblock C, Schwarz PE H, Perakakis N et al.The interface of COVID-19, diabetes, and depression. Discover Mental Health. 2022;2:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8886346</ArticleId><ArticleId IdType="pubmed">35253006</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenblock C, Todorov V, Kanczkowski W et al.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. Mol Psychiatry. 2020;25:1611&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204611</ArticleId><ArticleId IdType="pubmed">32382135</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaledi M, Haghighatdoost F, Feizi A et al.The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol. 2019;56:631&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">30903433</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina R, Iommi M, Rucci P et al.Is it time to consider depression as a major complication of type 2 diabetes? Evidence from a large population-based cohort study. Acta Diabetol. 2021;59:95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758621</ArticleId><ArticleId IdType="pubmed">34495396</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy T, Lloyd C E. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012;142:S8&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23062861</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Wang S, Zong Q Q et al.Prevalence of comorbid major depressive disorder in Type 2 diabetes: a meta-analysis of comparative and epidemiological studies. Diabet Med. 2019;36:961&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">31127631</ArticleId></ArticleIdList></Reference><Reference><Citation>Knol M J, Twisk J W, Beekman A T et al.Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49:837&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">16520921</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotella F, Mannucci E. Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. J Clin Psychiatry. 2013;74:31&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">23419223</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt R I, de Groot M, Golden S H. Diabetes and depression. Curr Diab Rep. 2014;14:491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4476048</ArticleId><ArticleId IdType="pubmed">24743941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellass S, Lister J, Kitchen CE W et al.Living with diabetes alongside a severe mental illness: a qualitative exploration with people with severe mental illness, family members and healthcare staff. Diabet Med. 2021;38:e14562.</Citation><ArticleIdList><ArticleId IdType="pubmed">33772867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>